David John Kuter MD DRPHIL
Professor of Medicine, Massachusetts General Hospital
Join to view full profile
55 Fruit StYaw 7b Hematology OncologyBoston, MA 02114
Phone+1 617-724-6193
Fax+1 617-643-1915
Dr. Kuter is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1978 - 1983
Harvard Medical SchoolClass of 1978
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology
Certifications & Licensure
MA State Medical License 1987 - 2027
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2016-2017
Clinical Trials
- Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
- Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
- Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Publications & Presentations
PubMed
- The hunt for a cure: modern medical approaches for immune thrombocytopenia.Debbie Jiang, David J Kuter
Expert Review of Hematology. 2026-07-01 - Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia.Tomás José González-López, Fernando Orza, Amalia Cuesta-García, Noelia Pérez-Gómez, José Luis Fedele
Blood Vessels, Thrombosis & Hemostasis. 2026-05-01 - Supportive strategies in thrombocytopenia: Platelet transfusion and beyond.Tomás José González-López, David J Kuter, Drew Provan
Blood Reviews. 2026-04-24
Journal Articles
- Romiplostim in Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia (ITP) for up to 1 Year and in Those with Chronic ITP for More Than 1 Year: A S...David J Kuter, Bhakti Mehta, British Journal of Haematology
- Presenting Signs and Patient Co‐Variables in Gaucher Disease: Outcome of the Gaucher Early Diagnosis Consensus (GED‐C) Delphi InitiativeDavid J Kuter, Neal J Weinreb, Internal Medicine Journal
Abstracts/Posters
- Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune ThrombocytopeniaDavid J. Kuter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesAmerican Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies2013 International Conference, Philadelphia, Pennsylvania, USA
- Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Other
- Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2012-07-24 - Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2013-01-30 - Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesDavid Kuter, MD, British Journal of Haematology
https://www.doximity.com/articles/d909d298-5043-4c91-b3f6-84a999dd1fef
UpToDate, Wolters Kluwer Health - 2012-09-07
Press Mentions
Mezagitamab in Patients with Immune ThrombocytopeniaJuly 14th, 2025- LUNA 3: Rilzabrutinib Meets Primary Endpoint in ITPDecember 31st, 2024
- Rilzabrutinib Found Safe and Effective for Refractory Immune ThrombocytopeniaDecember 13th, 2024
Grant Support
- MGH Transfusion Medicine And Hemostasis Network Clinical Core CenterNational Heart, Lung, And Blood Institute2009
- A Proteogenomic Analysis Of Platelets In Patients With Essential ThrombocythemiaNational Heart, Lung, And Blood Institute2007–2008
- A Proteogenomic Analysis Of Platelets In Patients With *National Heart, Lung, And Blood Institute2006
- Studies Of Rhutpo In ITP And Of Rvlla In Liver DiseaseNational Heart, Lung, And Blood Institute2002–2006
- Proteogenomic Analysis Of Platelets In ThrombocythemiaNational Heart, Lung, And Blood Institute2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
